Monthly Archives: February 2012

University of Maryland Professor To Head Accreditation Council for Pharmacy Education

Posted: Published on February 17th, 2012

Newswise — Robert Beardsley, RPh, PhD, has devoted his entire career to making pharmacists the best health care professionals they can be. In recognition of his outstanding leadership in the field, the Accreditation Council for Pharmacy Education (ACPE) has made Beardsley its top officer. The ACPE is an autonomous agency that determines the accreditation of U.S. professional degree programs in pharmacy and providers of continuing pharmacy education. It elected Beardsley president of its ruling board of directors for 2012-2013. Beardsley is a professor and vice chair for education in the Department of Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy in Baltimore, where he instructs students in the social behavioral aspects of pharmacy, with topics ranging from patient counseling to care of the terminally ill. For the past 15 years, Beardsley has taken part in ACPE's evaluation site visits to various pharmacy schools nationwide. He says, "The visits are designed to improve the quality of programs by evaluating their strengths and weaknesses." The visiting teams then make recommendations to the ACPE board for future action, such as to continue the school as is or to take some other action - from issuing warnings to calling for … Continue reading

Posted in Pharmacy | Comments Off on University of Maryland Professor To Head Accreditation Council for Pharmacy Education

Histogenics to Present at 7th Annual New York Stem Cell Summit

Posted: Published on February 17th, 2012

WALTHAM, Mass.--(BUSINESS WIRE)-- Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated. Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011. About Histogenics Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Histogenics to Present at 7th Annual New York Stem Cell Summit

World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

Posted: Published on February 17th, 2012

World Stem Cells, LLC Stem Cell Therapy at a state of the art clinic in beautiful Cancun. The clinic is staffed by top specialist in the field of stem cell implants and a new laboratory to support the stem cell treatments given. (PRWEB) February 16, 2012 World Stem Cells, LLC. contract laboratory Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.) a new adult stem cell laboratory being built in Cancun, Mexico to support Stem Cell research, stem cell clinical trials and stem cell treatments. This was accomplished by private funding in conjunction with World Stem Cells, LLC worldstemcells.com a US patient management company, Medicina Biocelular Avanzada , S.E. de C.V. a Mexican patient management company and Advanced Cellular Medicine Clinic of Cancun, a Stem Cell treatment Clinic owned and operated by Dr. Sylvia M. Abblitt a well known board certified hematologist and oncologist, in Cancun. Uniquely, Dr. Abblitt is one of a limited number of physicians licensed to perform autologous and allogeneic stem cell transplants. Dr. Abblitt has been utilizing stem cell therapies with successes for many years. She is the president and lab director of Advanced Cellular Engineering Lab (Ingenieria Celular Advanzada S.A. de C.V.). Her extensive … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on World Stem Cells, LLC. Stem Cell Treatments In Cancun at Advanced Cellular Medicine Clinic

Most epilepsy surgery candidates don't opt for it

Posted: Published on February 16th, 2012

Living with epilepsy can be arduous if symptoms aren't well-controlled. For some people, that means medication. For others, it may mean surgery. But despite a recent study showing that epilepsy surgery can be highly effective in the long term, just a fraction of those who suffer with the seizure disorder actually opt for it. Affecting some 3 million Americans and 50 million people worldwide, epilepsy is a neurological condition that produces brief disturbances in the brain's electrical functions that can cause seizures and other symptoms. According to the Epilepsy Foundation, in seven out of 10 cases, the cause of epilepsy isn't known; in other cases, head injuries, lack of oxygen during birth, brain tumors or infections such as meningitis and encephalitis are the culprits. Seizures can be a tremendous burden. For those who don't respond to medication, seizures may occur daily, weekly, monthly or even less frequently, but the results can be devastating. Those with epilepsy may not be allowed to drive, employment can be difficult and they're at risk for injuries, including falls and drowning because seizures are unpredictable. It's estimated that 60 percent to 70 percent of those with epilepsy remain seizure-free with medication. Those who don't respond … Continue reading

Comments Off on Most epilepsy surgery candidates don't opt for it

Epilepsy Community Has Major Concern Over Release of Anticonvulsant Drug Comparison Report

Posted: Published on February 16th, 2012

Newswise — WEST HARTFORD, CT, February 16 -- Leading representatives of the American Epilepsy Society, American Academy of Neurology, and the Epilepsy Foundation today reported they have grave concerns about the implications and potential misuse of the anticonvulsant (AED) drug comparisons study recently released by the U.S. Agency for Health Research and Quality (AHRQ). The study’s intent is to provide an evidence-based analysis of the Effectiveness and Safety of Antiepileptic Medications in Patients With Epilepsy. But the AHRQ report has little clinical value according to the specialists in neurology and epilepsy and could negatively impact patient care. The AHRQ report is an examination of the comparative efficacy, safety, and tolerability of newer versus older and innovator versus generic antiepileptic medications. The representatives and their organizations strongly support evidence–based medicine and comparative effectiveness research, which they believe improves quality of care. At issue, however, is the study focus, which fails to recognize the different types of epilepsy and deals with this multiform disorder as if it were a monolithic and homogeneous condition. The study further compares effectiveness of old-line anticonvulsants to newer epilepsy drugs irrespective of epilepsy type. Given that seizures have vastly different pathologies and the use of AEDs differs … Continue reading

Comments Off on Epilepsy Community Has Major Concern Over Release of Anticonvulsant Drug Comparison Report

New research fundraiser puts focus on autism center

Posted: Published on February 16th, 2012

A fundraising blitz by the Office of the Vice President for Research’s first development director hopes to make a proposed autism research center a reality. The University has stayed committed to the autism and neuro-developmental disorder center since its conception in 2010, but Vice President for Research Leo Chalupa said the project cannot move forward unless newly hired Heather Russell can raise the capital for it. Chalupa has said $10 million is needed to completely launch an autism research center, but University spokeswoman Jill Sankey said Tuesday that the development of a center could begin with a portion of that sum raised. Chalupa said Russell, a former development director for the Texas-based Autism Treatment Center who started at the University last week, has a tough task ahead of her. “The reason autism was targeted for raising money is because it’s expensive,” Chalupa said. “It’s very broad. It varies in everything from lab work with animals to human brain imaging to things like that. So it’s expensive.” He has set a goal for Russell to raise $2 million to $3 million this year, which could get a lift from forging partnerships with private foundations, and continue fundraising over the next three … Continue reading

Comments Off on New research fundraiser puts focus on autism center

Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss

Posted: Published on February 16th, 2012

SAN BRUNO, Calif., Feb. 16, 2012 /PRNewswire/ -- Cord Blood Registry (CBR) is the exclusive partner for a growing number of clinical researchers focusing on the use of a child's own cord blood stem cells to help treat pediatric brain injury and acquired hearing loss. To ensure consistency in cord blood stem cell processing, storage and release for infusion, three separate trials have included CBR in their FDA-authorized protocol—including two at the University of Texas Health Science Center at Houston (UTHealth) working in partnership with Children's Memorial Hermann Hospital, and a third at Georgia Health Sciences University, home of the Medical College of Georgia (MCG). This makes CBR the only family stem cell bank pairing researchers with prospective patients for these studies.  (Logo: http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO) "Partnering with a series of specialists who want to research the use of a child's own newborn blood stem cells on a variety of disease states allows CBR to help advance medical research for regenerative therapies by connecting the child whose family banked with CBR to appropriate researchers," said Heather Brown, MS, CGC, Vice President of Scientific & Medical Affairs at Cord Blood Registry.  "The pediatric specialists from UTHealth, Children's Memorial Hermann Hospital, and Georgia Health Sciences … Continue reading

Posted in Brain Injury Treatment | Comments Off on Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss

Renowned Dr. Oz and the Acclaimed Financial Times Now Have Featured Dr. Lionel Bisson, Founder of …

Posted: Published on February 16th, 2012

Wall Street Executives and soccer moms alike are visiting AntiAgingMedicine.md or TestosteroneReplacementTreatment.com and learning how Dr. Lionel Bissoon, D.O has helped thousands of his patients look & feel their best with testosterone replacement therapy. New York, NY (PRWEB) February 16, 2012 As people age, there are physical changes that take place in the body. These changes can be significant and life changing. For years, men and women had to suffer in silence from decline in testosterone, PMS, menopause and weight gain. However, hormone therapy has transformed millions of people’s lives. Dr. Lionel Bissoon a world-renowned expert on the use of hormone replacement therapy has discovered effective treatments for these hormone-related medical conditions and founded TestosteroneReplacementTreatment.com and AntiAgingMedicine.md so that people could learn more and improve their lives. Dr. Lionel Bissoon, a world-renowned expert on the use of hormone replacement therapy, has treated tens of thousands of men and women for decades. His peers highly praise him as a leader in Testosterone Replacement Treatment. He is a nationally recognized trailblazer for improving the lives of tens of thousands of men and women and a leading voice in the hormone therapy community. Dr. Bissoon recently featured in the prestigious Financial Times regarding … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Renowned Dr. Oz and the Acclaimed Financial Times Now Have Featured Dr. Lionel Bisson, Founder of …

Research and Markets: Targeting Cancer Stem Cells: Therapeutic Strategies, Pipeline, Biomarkers and Opportunities 2011

Posted: Published on February 16th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/0a3b55/targeting_cancer_s) has announced the addition of the "Targeting Cancer Stem Cells: Therapeutic Strategies, Pipeline, Biomarkers and Opportunities 2011" report to their offering. Cancer Stem Cell (CSC) research has accelerated in recent years and considerable efforts are being made to develop novel agents that target these cells. Today, more than forty companies and commercial research groups are evaluating 20+ strategies and 50 candidate molecules, in the hope of making new advances in this area. CSCs are being targeted using novel single agents as well as combinations, based on new and established classes. This 2011 report gives a comprehensive update on current therapeutic and diagnostic development in this field, on the drug development pipeline and the most promising research areas. New therapeutic and diagnostic opportunities in this field are also presented. Background: Many cancers contain a subset of stem-like cells believed to play a critical role in the development and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreatic, colon, brain, lung and other cancers. Findings suggest that CSCs are able to seed new tumour formation and drive metastasis. CSCs also show resistance to a number … Continue reading

Posted in Stem Cell Research | Comments Off on Research and Markets: Targeting Cancer Stem Cells: Therapeutic Strategies, Pipeline, Biomarkers and Opportunities 2011

Why the Stem Cell Fight Should, at Last, Be Over | The Intersection

Posted: Published on February 16th, 2012

My latest Science Progress column reacts to the new finalized stem cell guidelines promulgated by the National Institutes of Health this week. First, I give the background on Bush’s awful policy, finally superseded: The Bush administration’s increasingly unpopular policy, you’ll recall, stated that no stem cell lines derived from blastocysts after the date of the former president’s August 9, 2001 speech on the matter could be used in research receiving federal funds. This raised a host questions, both about ethics and also about coherence—for how could a rule based simply on which day Bush gave his speech have any moral authority? The policy lacked scientific authority as well, as it was soon revealed that Bush’s promise of “more than sixty genetically diverse” stem cell lines for federally funded research was simply bogus and based on a gross overestimate of the number of available lines. There were really only 21, and “genetically diverse” was a dubious assertion to boot. So the Bush policy wound up constraining research far more than it had at first appeared, and far more than promised. This story of scientific carelessness (or worse) during the president’s nationally televised stem cell address has now been told and retold, … Continue reading

Posted in Stem Cell Research | Comments Off on Why the Stem Cell Fight Should, at Last, Be Over | The Intersection